Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
11.01
-0.49 (-4.26%)
At close: Jul 17, 2026, 4:00 PM EDT
11.00
-0.01 (-0.09%)
After-hours: Jul 17, 2026, 4:10 PM EDT
Akari Therapeutics, Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Akari Therapeutics, stock have an average target of $26.78, which predicts a 143.23% increase from the current stock price of 11.01.
Price Target: $26.78 (+143.23%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Akari Therapeutics, stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $27 | Buy | Reiterates | $27 | +145.23% | Jul 1, 2026 |
| Maxim Group | Maxim Group | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Apr 8, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-12.00
EPS Next Year
-14.00
from -12.00
EPS and Forward PE are based on non-GAAP adjusted numbers.